Menu
a new paradigm for treating allergies
Glyco-immunology is an emerging scientific field that is rapidly evolving.
GlycoTreat’s scientific co-founder, Prof. Yvette van Kooyk, Molecular Cell Biology and Immunology at Amsterdam UMC, was awarded the 2019 Spinoza Prize for her groundbreaking research discovering that specific complex sugar chains can modify the immune system by suppressing or activating the immune response.
Utilizing this unique glycan-mediated immune pathway, redirecting the immune system to develop tolerance towards specific antigens, GlycoTreat is now at the forefront of bringing a whole new generation of short-term Allergen ImmunoTherapy to the clinic.
Our mission is to develop a cure for the more than 50% of school children that suffer from one or more allergies.
Technological advances have revealed the vital role played by cell surface glycans in regulating the immune response.
GlycoTreat has discovered how these structures can be manipulated to suppress the immune system and treat allergic diseases.
50% of schoolchildren in Europe suffer from one or more allergies, making allergy becoming a true epidemic.
Current immunotherapy is based on desensitization and can take up to 3-5 years (60 injections) to reduce allergy symptoms with the risk of severe adverse reactions.
Food allergies are an increasing medical concern, as 8% of children suffer from food allergies, from which 38.7% have a history of serious reactions requiring hospitalization.
Our pipeline of pioneering glyco-immunology therapies in allergies
GlycoTreat BV.
Koningin Beatrixplantsoen 28
3818 ZB Amersfoort
The Netherlands
